1Buse JB, Patrizia C, Kenneth H, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the U- nited States [J]. J Clini Epidemiol, 2003, 56 (2) : 164-170.
2Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk fac- tor for antipsychoticnon compliance [J]. Schizophr Res, 2004, 66 (1): 51-57.
3Geiger BM, Haburcak M, Avena NM, et al. Deficits of me- solimbie dopamine neurotransmission in rat dietary obesity [J]. Neurosci, 2009, 159 (4): 1193- 1199.
4Coccurello R, Moles A. Potential mechanisms of atypical antip sychotic-induced metabolic derangement: Clues for understand- ing obesity and novel drug design [J]. Pharmacol & Ther, 2010, 127 (3): 210-251.
5Thanos PK, Michaelides M, Piyis YK, et al. Food restriction markedly increases dopamine d2 receptor (D2R) in a rat model of obesity as assessed with in-vivo mu PET Imaging ( C-11 raclopride) and in-vitro ( H-3 spiperone) autoradiography [J]. Synapse, 2008, 62 (1): 50-61.
6Yoon S, Noh JS, Choi SY, et al. Effects of atypical antipsy- chotic drugs on body weight and food intake in dopamine D2 re- ceptor knockout mice [J]. Biochem Biophys Res Commun, 2010, 393 (2): 235-241.
7Kim HC, Jung SW, and Kim DK. Antipsychoties-indueed weight gain is associated with therapeutic response and the poly- morphism of dopamine Da receptor gene in Korean schizophrenia [J]. Eur Neuropsyehopharmaeol, 2006, 16 (4) : 215 -215.
8Dourish CT, Hutson PH, Curzon G. Low doses of the putative serotonin agonist 8-hydroxy-2- (di-n-propylamino) tetralin (8- OH-DPAT) elicit feeding in the rat[J]. Psychopharmacol, 1985, 86 (1-2): 197- 204.
9Clifton PG, Lee MD, Dourishct. Similarities in the action of Ro 60 0175, a 5 HT2C receptor agonist, and d-fenfluramine on feeding patterns in the rat [J]. Psychopharmacol, 2000, 152 (3) :256-267.
10Voigt JP, Schade R , Fink H, et al. Role of 5-HT1A recep- tors in the control of food intake in obese Zucker rats of differ- ent ages [J].Pharmacol Biochem Behav, 2002, 72 (1-2):403-409.
